Career Development Award in HER2 supports early-career pathologists’ research to optimize and validate HER2 testing in solid tumors beyond breast and gastric cancer, improving patient selection for therapy.
The application deadline has been extended from November 12, 2026, to December 14, 2026.
Funder: College of American Pathologists Foundation
Due Dates: December 1, 2026 (Application deadline, extended)
Funding Amounts: Up to $120,000 USD for a 12-month project, February 2027–February 2028
Summary: Supports quantitative pathology research to optimize and validate HER2 immunohistochemistry in solid tumors beyond breast and gastric cancer.
Key Information: Applicants need at least three years of relevant surgical pathology sign-out experience; trainees cannot apply independently.
The College of American Pathologists (CAP) Foundation supports quantitative pathology research to optimize and validate HER2 immunohistochemistry (IHC) assays in solid tumors beyond breast and gastric cancer. The award addresses gaps in standardized testing and aims to generate evidence for consistent, accurate patient selection for anti-HER2 antibody-drug conjugate therapies and assessment of HER2 testing’s clinical utility.
The program prioritizes early-career pathologists and pairs research with mentored experience and skills development. Projects should optimize and validate assays using tumor-specific criteria and rigorous analytic validation methods. Additional objectives may examine HER2 expression patterns, correlations with other diagnostic methods, or evidence-based recommendations for future CAP guidelines. Three identified priorities are colorectal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer.